| Completed | N/A | 1976 | US | sipuleucel-T, PROVENGE, APC8015 | Dendreon | Advanced Prostate Cancer, Prostatic Neoplasms | 01/17 | 01/17 | | |
NCT02232230: A Multicenter Trial Enrolling Men With Advanced Prostate Cancer Who Are to Receive Combination Radiation and Sipuleucel-T |
|
|
| Completed | N/A | 20 | US | Provenge | GenesisCare USA, Dendreon | Castrate Refractory Metastatic Prostate Cancer (mCRPC) | 06/18 | 06/18 | | |
NCT01833208: Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T |
|
|
| Completed | N/A | 15 | US | Laboratory Biomarker Analysis, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, Irradiation, RADIATION, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation | Roswell Park Cancer Institute, Dendreon | Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer | 08/18 | 01/21 | | |
| Completed | N/A | 38 | US | CTC biomarker expression prevalence | Duke University, Janssen Research & Development, LLC | Prostate Cancer | 06/19 | 06/19 | | |